Efficacy and tolerability of aripiprazole: A 26-week switching study from oral antipsychotics

Jung Sun Lee, Seockhoon Chung, Joon Noh Lee, Jun Soo Kwon, Do Hoon Kim, Chul Eung Kim, Kang Seob Oh, Yang Whan Jeon, Min-Soo Lee, Myung Ho Lim, Hye Ryein Chang, Chang Yoon Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). Methods: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. Results: At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. Conclusion: This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.

Original languageEnglish
Pages (from-to)189-195
Number of pages7
JournalPsychiatry Investigation
Volume7
Issue number3
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

faropenem medoxomil
Antipsychotic Agents
Confidence Intervals
Schizophrenia
Aripiprazole
Age Distribution
Sleep Initiation and Maintenance Disorders
Psychotic Disorders
Nausea
Headache
Outpatients
Maintenance

Keywords

  • Aripiprazole
  • Maintenance
  • Schizoaffective disorder
  • Schizophrenia
  • Switch

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Lee, J. S., Chung, S., Lee, J. N., Kwon, J. S., Kim, D. H., Kim, C. E., ... Kim, C. Y. (2010). Efficacy and tolerability of aripiprazole: A 26-week switching study from oral antipsychotics. Psychiatry Investigation, 7(3), 189-195. https://doi.org/10.4306/pi.2010.7.3.189

Efficacy and tolerability of aripiprazole : A 26-week switching study from oral antipsychotics. / Lee, Jung Sun; Chung, Seockhoon; Lee, Joon Noh; Kwon, Jun Soo; Kim, Do Hoon; Kim, Chul Eung; Oh, Kang Seob; Jeon, Yang Whan; Lee, Min-Soo; Lim, Myung Ho; Chang, Hye Ryein; Kim, Chang Yoon.

In: Psychiatry Investigation, Vol. 7, No. 3, 01.09.2010, p. 189-195.

Research output: Contribution to journalArticle

Lee, JS, Chung, S, Lee, JN, Kwon, JS, Kim, DH, Kim, CE, Oh, KS, Jeon, YW, Lee, M-S, Lim, MH, Chang, HR & Kim, CY 2010, 'Efficacy and tolerability of aripiprazole: A 26-week switching study from oral antipsychotics', Psychiatry Investigation, vol. 7, no. 3, pp. 189-195. https://doi.org/10.4306/pi.2010.7.3.189
Lee, Jung Sun ; Chung, Seockhoon ; Lee, Joon Noh ; Kwon, Jun Soo ; Kim, Do Hoon ; Kim, Chul Eung ; Oh, Kang Seob ; Jeon, Yang Whan ; Lee, Min-Soo ; Lim, Myung Ho ; Chang, Hye Ryein ; Kim, Chang Yoon. / Efficacy and tolerability of aripiprazole : A 26-week switching study from oral antipsychotics. In: Psychiatry Investigation. 2010 ; Vol. 7, No. 3. pp. 189-195.
@article{8e36502f2d9b4e40a492ca1b3317b8fa,
title = "Efficacy and tolerability of aripiprazole: A 26-week switching study from oral antipsychotics",
abstract = "Objective: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). Methods: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95{\%} confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. Results: At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95{\%} CI: 2.72-3.12) in the aripiprazole group and 2.81 (95{\%} CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8{\%} and 72.6{\%}, respectively, and 80.2{\%} of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. Conclusion: This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.",
keywords = "Aripiprazole, Maintenance, Schizoaffective disorder, Schizophrenia, Switch",
author = "Lee, {Jung Sun} and Seockhoon Chung and Lee, {Joon Noh} and Kwon, {Jun Soo} and Kim, {Do Hoon} and Kim, {Chul Eung} and Oh, {Kang Seob} and Jeon, {Yang Whan} and Min-Soo Lee and Lim, {Myung Ho} and Chang, {Hye Ryein} and Kim, {Chang Yoon}",
year = "2010",
month = "9",
day = "1",
doi = "10.4306/pi.2010.7.3.189",
language = "English",
volume = "7",
pages = "189--195",
journal = "Psychiatry Investigation",
issn = "1738-3684",
publisher = "Korean Neuropsychiatric Association",
number = "3",

}

TY - JOUR

T1 - Efficacy and tolerability of aripiprazole

T2 - A 26-week switching study from oral antipsychotics

AU - Lee, Jung Sun

AU - Chung, Seockhoon

AU - Lee, Joon Noh

AU - Kwon, Jun Soo

AU - Kim, Do Hoon

AU - Kim, Chul Eung

AU - Oh, Kang Seob

AU - Jeon, Yang Whan

AU - Lee, Min-Soo

AU - Lim, Myung Ho

AU - Chang, Hye Ryein

AU - Kim, Chang Yoon

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objective: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). Methods: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. Results: At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. Conclusion: This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.

AB - Objective: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). Methods: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. Results: At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. Conclusion: This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.

KW - Aripiprazole

KW - Maintenance

KW - Schizoaffective disorder

KW - Schizophrenia

KW - Switch

UR - http://www.scopus.com/inward/record.url?scp=77957732981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957732981&partnerID=8YFLogxK

U2 - 10.4306/pi.2010.7.3.189

DO - 10.4306/pi.2010.7.3.189

M3 - Article

C2 - 20927307

AN - SCOPUS:77957732981

VL - 7

SP - 189

EP - 195

JO - Psychiatry Investigation

JF - Psychiatry Investigation

SN - 1738-3684

IS - 3

ER -